Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago. These figures are ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

My monthly update and commentary on the top dividend stock picks from Barron's Better Bets, July 2025 edition. Read the full ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...

Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is set to launch a pivotal Phase 3 clinical study titled ‘A ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...